Latest Period
Q1 2026
Security Snapshot
OKYO Pharma Ltd - Ordinary Shares, no par value (OKYO) Institutional Ownership
CUSIP: G6724L116
13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026
Institutions Reporting
12
Shares (Excl. Options)
6,389,739
Price
$1.61
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Ordinary Shares, no par value
- Symbol
- OKYO on Nasdaq
- Shares outstanding
- 52,174,143
- Price per share
- $1.58
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 6,389,739
- Total reported value
- $10,287,479
- % of total 13F portfolios
- 0%
- Share change
- +5,724,445
- Value change
- +$9,147,727
- Number of holders
- 12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- OKYO - OKYO Pharma Ltd - Ordinary Shares, no par value is tracked under CUSIP G6724L116.
- 12 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 10 to 12 between Q4 2025 and Q1 2026.
- Reported value moved from $1,147,535 to $10,287,479.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 12 institutions filings for Q1 2026.
Security key
G6724L116
Latest holder period
Q1 2026
13F holders
12
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
OKYO full holder history
OKYO Pharma Ltd SEC filings
OKYO Pharma Ltd company facts
OKYO Pharma Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G6724L116:
Significant Owners of OKYO Pharma Ltd - Ordinary Shares, no par value (OKYO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sirenia Capital Management LP | 7.7% | $6,202,703 | 4,054,054 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Chernett Jorey | 9.5% | +21% | $11,824,823 | +$2,541,903 | 3,802,194 | +27% | Chernett Jorey | 31 Dec 2025 |
| Woodline Partners LP | 7% | $5,587,851 | 3,652,190 | Woodline Partners LP | 31 Mar 2026 | |||
| Fonda Laura Natalia Monica | 5% | $3,856,902 | 1,928,451 | LAURA NATALIA MONICA FONDA | 22 Jul 2025 | |||
| Dauntless Investment Group, LLC | 1.2% | -85% | $1,466,437 | -$6,066,133 | 471,523 | -81% | Dauntless Investment Group, LLC | 31 Dec 2025 |
As of 31 Mar 2026, 12 institutional investors reported holding 6,389,739 shares of OKYO Pharma Ltd - Ordinary Shares, no par value (OKYO). This represents 12% of the company’s total 52,174,143 outstanding shares.
Top 14 Institutional Shareholders
The largest institutional shareholders of OKYO Pharma Ltd - Ordinary Shares, no par value (OKYO) together control 12% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Woodline Partners LP | 7% | 3,652,190 | 0.02% | $5,880,026 | |
| Maven Securities LTD | 2.3% | 1,175,535 | 0.11% | $1,892,611 | |
| Stonepine Capital Management, LLC | 1.6% | 850,000 | 1.2% | $1,368,500 | |
| Balyasny Asset Management L.P. | 1.1% | 584,796 | 0% | $941,522 | |
| UBS Group AG | 0.11% | 59,760 | +2651% | 0% | $96,214 |
| XTX Topco Ltd | 0.07% | 37,652 | +114% | 0% | $60,620 |
| Cerity Partners LLC | 0.02% | 12,812 | 0% | 0% | $20,627 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.02% | 12,090 | 0% | 0% | $19,464 |
| Dauntless Investment Group, LLC | 0.01% | 3,819 | -99% | 0.02% | $6,149 |
| EFG International AG | 0% | 923 | 0% | 0% | $1,486 |
| OSAIC HOLDINGS, INC. | 0% | 152 | 0% | 0% | $244 |
| MORGAN STANLEY | 0% | 10 | 0% | 0% | $16 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 0% | 0 | -100% | $0 | |
| RENAISSANCE TECHNOLOGIES LLC | 0% | 0 | -100% | $0 |
Institutional Holders of OKYO Pharma Ltd - Ordinary Shares, no par value (OKYO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 6,389,739 | $10,287,479 | +$9,147,727 | $1.61 | 12 |
| 2025 Q4 | 665,294 | $1,147,535 | -$2,989,322 | $2.07 | 10 |
| 2025 Q3 | 2,570,815 | $5,141,930 | -$400,030 | $2.00 | 8 |
| 2025 Q2 | 2,770,797 | $1,479,794 | +$329,427 | $2.57 | 5 |
| 2025 Q1 | 2,075,082 | $2,634,954 | +$1,447,536 | $1.27 | 7 |
| 2024 Q4 | 1,026,179 | $1,179,953 | +$28,548 | $1.15 | 7 |
| 2024 Q3 | 1,001,353 | $1,021,431 | -$19,942 | $1.03 | 6 |
| 2024 Q2 | 1,010,912 | $1,210,177 | +$115,592 | $1.20 | 7 |
| 2024 Q1 | 913,582 | $1,363,796 | +$79,673 | $1.50 | 6 |
| 2023 Q4 | 855,098 | $1,513,021 | +$1,343,703 | $1.77 | 7 |
| 2023 Q3 | 95,254 | $175,728 | +$153,652 | $1.85 | 7 |
| 2023 Q2 | 11,933 | $13,669 | +$13,669 | $1.15 | 1 |